Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2007, p. 8571-8582, Vol. 27, No. 24
0270-7306/07/$08.00+0 doi:10.1128/MCB.01350-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Edris A. F. Mahtab,2
Lambertus J. Wisse,2
Jun Hou,1
Frank Grosveld,1
Guntram Suske,3
Sjaak Philipsen,1* and
Adriana C. Gittenberger-de Groot2*
Department of Cell Biology, Erasmus MC, Rotterdam, The Netherlands,1 Department of Anatomy and Embryology, LUMC, Leiden, The Netherlands,2 Institute for Molecular Tumor Research, Marburg, Germany3
Received 27 July 2007/ Returned for modification 8 September 2007/ Accepted 27 September 2007
|
|
|---|
|
|
|---|
We found that Sp3–/– fetuses in the C57BL/6 background display a high prenatal mortality rate. The majority of these fetuses die in utero before E18.5, suggesting that lung failure is not the main cause of the previously described immediate postnatal lethality of Sp3–/– fetuses (6). Congenital heart defects are a common cause of pre- and perinatal mortality. Early during embryogenesis, cells of the lateral mesoderm become committed to the cardiac fate and start to express cardiac-specific genes (16). The newly formed cardiac cells assemble into a beating linear heart tube that undergoes rightward looping. This process is essential to position the in- and outflow tracts in close proximity to the developing four heart chambers that acquire their own specific morphological characteristics. A complex transcriptional network controls these processes (12, 16).
To investigate the potential cause of the high prenatal mortality rate of Sp3–/– fetuses, we performed a detailed morphological study of heart development. This was combined with a study of the expression of over 15 cardiac marker genes in the Sp3 null hearts at different stages of development and with microarray analysis of gene expression at E12.5. Collectively, our results demonstrate that Sp3 is required for normal cardiac development and suggest a crucial role for Sp3 in myocardial differentiation, possibly resulting from disturbed cell-cell interactions.
|
|
|---|
In situ hybridization. The probes for Tgfß1, Tgfß2, and Tgfß3 have been described previously (37); the probe for Mlc2v was a gift from A. F. Moorman. Other probe sequences were generated via PCR and subsequently cloned using the pGEM-T-Easy vector system I A1360 (Promega, Madison, WI) and sequenced. Riboprobes were labeled with 35S-UTP (SJ603; 1,000 Ci/mmol) (Amersham, Little Chalfont, United Kingdom), and hybridization was performed as described previously (25). PCR primers used to generate the probes were as follows (s, sense; as, antisense): Anf, 5'-GACAGCAAACATCAGATCGT-3' (s) and 5'-CTCTGGGCTCCAATCCTGTC-3' (as) (461-bp fragment); Carp, 5'-AGGAGCTGGTAACAGGCAAA-3' (s) and 5'-TTCAGGACATCTGCGTTTCC-3' (as) (489-bp fragment); eHAND, 5'-TGCAACTACCCACTAGGATC-3' (s) and 5'-TTCAGCAACGAATGGGAACG-3' (as) (579-bp fragment); Gata4, 5'-AATGCCTGTGGCCTCTATCA-3' (s) and 5'-CGCTGATTACGCGGTGATTA-3' (as) (621-bp fragment); Gata5, 5'-GACTTTGCCTTCACCTCCT-3' (s) and 5'-AGTCCTGCGTCTGTAAGCAA-3' (as) (541-bp fragment); Irx4, 5'-ATGCTGGCAAAGACGACAAG-3' (s) and 5'-GGTGGCCCAGGCCTGGTTCA-3' (as) (623-bp fragment); Mlc2a, 5'-GCACAACGTGGCTCTTCTAA-3' (s) and 5'-GTGGGTGATGATGTAGCAGA-3' (as) (455-bp fragment); Sp3, 5'-TTGGCTTCTGCACAGTTAGG-3' (s) and 5'-CATTGTCTGAGAACTTCCCG-3' (570-bp fragment); and Tbx5, 5'-AAGACACCTTCTATCGCTCG-3' (s) and 5'-TATTCTCACTCCACTCTGGC-3' (as) (504-bp fragment).
Immunohistochemistry. The following primary antibodies were used: actin HHF35 (Dako, Glostrup, Denmark); Mlc2a (a kind gift from S. W. Kubalak); and Nkx2.5 (sc-8697), Sp3 (sc-13018), Wt1 (sc-192), and E-cadherin (sc-7870) (all from Santa Cruz Biotechnology, Santa Cruz, CA). As secondary antibodies, we used biotinylated goat anti-rabbit BA-1000 for Mlc2a, Sp3, Wt1, and E-cadherin; biotinylated rabbit anti-goat PK-6105 (Vector Laboratories, Burlingame, CA) for Nkx2.5; and rabbit anti-mouse P0260 (Dako, Glostrup, Denmark) and goat anti-rabbit and rabbit peroxidase anti-peroxidase (Nordic Immunological Laboratories, Tilburg, The Netherlands) for actin. The Vectastain ABC kit HRP PK6100 (Vector Laboratories, Burlingame, CA) was used as the third step for biotinylated secondary antibodies. For visualization, sections were incubated with 400 µg/ml 3,3' diaminobenzidine tetrahydrocholoride (D5637; Sigma-Aldrich, St. Louis, MO) in 0.05 mM Tris-maleate buffer, pH 7.6, and finally counterstained with Mayer's hematoxylin.
Morphometry and 3D reconstruction. Myocardial sampling and volume estimation for 15 wild-type (WT) and 16 Sp3–/– hearts were performed as described previously (23). For the study of looping, micrographs were made of E10.5 Sp3+/+ and Sp3–/– hearts. The 3D reconstructions were made as described previously (29) using the AMIRA software package (Template Graphics Software, San Diego, CA). Statistical analysis was performed with an independent sample t test using the SPSS 11.0 software program (SPSS Inc, Chicago, IL).
Gel retardation analysis. The sequences of the oligonucleotides used are as follows (the sense strand is given): C1, 5'-ACCCCTGCCCCCACCAGTGGC-3'; C2, 5'-TAAGAACCCCCACCCCACTTCA-3'; C3, 5'-TTCGCTCCACCCACGATGCGT-3'; C4, 5'-TTGGCTCCACCCATAAGAAGC-3'; C5, 5'-ACCTTTCCCCACCCAGGTGAT-3'; and Sp, 5'-TTATGGGCGGAGTTAGGGGCGGGACTAT-3'.
Samples were incubated for 30 min at room temperature, loaded on a 4% polyacrylamide-0.5x Tris-borate-EDTA gel, and run at 250 V for 2 h at room temperature. Antibodies against Sp1 and Sp3 were used at a 1:16 dilution in the binding reactions (6). Nuclear protein isolation was performed as described previously (1).
ChIP assays. Hearts were isolated from E14.5 WT embryos and collected in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, followed by homogenization with a 1-ml glass homogenizer (pestle B). Chromatin immunoprecipitation (ChIP) was performed as described previously (42) using either Sp3 (sc-644), Nkx2.5 (sc-8697), or preimmune immunoglobulin G (IgG) antibody (all from Santa Cruz Biotechnology, Santa Cruz, CA). PCR was performed on an MJ Research Opticon 2 PCR machine, using SYBR green to measure amplification products (Bio-Rad Laboratories, Hercules, CA). Primers were used to detect the upstream region of the Carp promoter (5'-ATCACCTGGGTGGGGAAAGGT-3' and 5'-TTGGCTCCACCCATAAGAAGC-3') or an area of the Gata2 gene that is not though to interact with either Sp3 or Nkx2.5 (5'-CCGGGCAGATAACGATTGG-3' and 5'-TTCATCTCGGCCGGCTAAT-3'). The enrichment of Carp sequences was calculated relative to the amplification efficiency of the Gata2 sequences, normalized to the ratio observed before the ChIP reactions.
Quantitative RT-PCR analysis. Total RNA was isolated from E14.5 WT and Sp3–/– hearts and subjected to quantitative reverse transcription-PCR (RT-PCR) analysis for the quantitation of gene expression (13). The primers used were 5'-CGACTCTTGATGACCTTCGG-3' and 5'-ATTGCTTTGGTTCCACTCTG-3' for Carp and 5'-TCACCATTTCCGACTGTGGAC-3' and 5'-ACAGGACATTGCGAGCAGATG-3' for cyclophilin A (Ppia), which was used as an internal standard to normalize for the amount of template used in the reactions.
Microarray analysis. Hearts were dissected from E12.5 WT and Sp3–/– embryos, and RNA was isolated from individual hearts. Total RNA (5 µg) was used for labeling and hybridization to 430 2.0 Gene Chips (Affymetrix, Santa Clara, CA). Data extraction and normalization were done as described previously (51) using Affymetrix Gene Chip Operating Software (GCOS) version 1.4. The overall intensity value of each Gene Chip was scaled to an average value of 200 according to the method of global scaling provided by GCOS. Intensity values of between 0 and 30 were set to 30. An unsupervised correlation analysis using all the probe sets expressed above the detection level in at least one of the samples was performed with the OmniViz correlation tool (OmniViz, Maynard, MA); this measures correlation patterns by use of Pearson's correlation coefficient. We used robust multichip average normalization to obtain a list of differentially expressed probe sets (27), using a fold change of >1.5 and false discovery rate of 0.01 as criteria. This list was used for cluster analysis by standard hierarchical clustering methods with similarity measured by Euclidean distance, provided by OmniViz software. Potentially relevant biological processes were determined with Ingenuity Pathways Analysis software (Ingenuity, Redwood, CA). Functional annotation was manually curated using the Mouse Genome Informatics website from The Jackson Laboratory (Bar Harbor, ME) (http://www.informatics.jax.org); The Online Mendelian Inheritance in Man McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD); the National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD) (http://www.ncbi.nlm.nih.gov/omim/); and the Ensembl genome database at the European Bioinformatics Institute (Hinxton, United Kingdom) (http://www.ensembl.org/) (July 2007).
Microarray accession number. Microarray data have been deposited at http://www.ncbi.nlm.nih.gov/geo (GSE9124).
|
|
|---|
To find developmental defects that might cause this late embryonic lethality, we studied the Sp3–/– embryos in more detail. In addition to the previously reported growth retardation of Sp3–/– embryos (6), we often observed nuchal edema in the mutants at E14.5 (Fig. 1a and d). This indicates that cardiac dysfunction may contribute to the prenatal mortality of the Sp3–/– embryos. Consistent with this notion, histological sections of E14.5 Sp3–/– hearts revealed an array of severe cardiac defects. In 15/17 Sp3–/– hearts the aorta and the pulmonary trunk were both positioned side by side (Fig. 1b and e) with the aorta connecting to the right ventricle (not shown). In all cases the arterial trunk had become septated, so no persistent truncus arteriosus was observed. Atrioventricular canal malformations were found in 11/17 cases showing a common atrioventricular valve, an atrioventricular septal defect (Fig. 1c, f, and g), or a straddling tricuspid valve (not shown).
![]() View larger version (117K): [in a new window] |
FIG. 1. Sp3–/– embryos display cardiac abnormalities. (a and d) The majority of the Sp3–/– embryos are edematous (arrows in panel d) at E14.5, which is suggestive of cardiac dysfunction. (b, c, and e to j) E14.5 sections of the heart stained for actin. In a WT heart (Sp3+/+) the pulmonary trunk (Pt) arises from the right ventricle (RV) (b), while in the mutant (e) the Pt and aorta (Ao) are side by side. At the level of the AVC, an atrioventricular septal defect (asterisk) occurs with a free hanging underrim of the atrial septum (AS) (f). The atrioventricular septal defect has a left dominance but is also connected to the RV, as is evident from a more posterior section of the same heart (g). In Sp3–/– hearts the myocardium is spongy with perforations (g and h) allowing for direct subendocardial-to-subepicardial contact, indicated by arrows (h). (i and j) Normal epicardial (EP) covering (i) compared to epicardial blebbing (EPB) in a mutant heart (j). LA, left atrium; LV, left ventricle; RA, right atrium. Bars; 100 µm (b, c, and e to h) and 50 µm (i and j).
|
|
View this table: [in a new window] |
TABLE 1. Myocardial volumes of Sp3–/– hearts during development
|
![]() View larger version (69K): [in a new window] |
FIG. 2. Morphological analysis of Sp3–/– embryonic hearts. (a to d) 3D reconstructions of a WT (a and c) and an Sp3–/– (b and d) embryonic heart at E10.5. Color codes: light brown, atria (A) and ventricles (V); pink, AVC; blue, outflow tract cushions (OFT); red, arteries (Art). The outer surface of the heart (a and b) shows the different relative positions of the cardiac segments in the Sp3–/– embryo. In the WT heart, the AVC and OFT cushions meet at the inner curvature (arrow in panel c), while in the knockout there is a wide inner curvature and separation of the cushions (arrow in panel d). (e to h) Sections of a WT (e and g) and an Sp3–/– (f and h) heart, stained for actin, show at E12.5 that in the Sp3–/– embryo the septation of the aortic sac (Aos) is not yet complete (f) compared to in the normal embryo (e), where the aorta (Ao) and pulmonary trunk (Pt) are already separated. At the atrioventricular canal level (g) in the WT, the AVC tissue is already fused with the cushion tissue (arrowhead) at the base of the atrial septum (AS). In the mutant heart (h), a common valve is shown. Small lateral cushions are present (arrows), and the cushion tissue at the base of the AS is not connected to the remaining AVC tissue (small patch in the middle). Bars, 200 µm.
|
Sp3 expression in the developing heart. Since the expression pattern of Sp3 in the heart might provide clues to explain the phenotype of the Sp3 null mutation, we analyzed expression of the Sp3 protein during cardiac development. Nuclear staining of Sp3 was already detected at E9.5 in the myocardium and endocardium as well as in the cells of the endocardial cushion tissue (Fig. 3a to c). This persisted in later stages in the Anlage of the semilunar and atrioventricular valves (Fig. 3d, e, g, and h to j). A somewhat mosaic positivity of myocardial cells was observed in the atria and ventricles through E12.5 and E14.5 (Fig. 3i and k). At these stages there was a clearly marked expression in the neural crest-derived mesenchyme (Fig. 3h), the epicardium (Fig. 3i and j) and the smooth muscle cells of the vascular wall (Fig. 3d, e, and h). Thus, while there appears to be some variation in expression levels, we conclude that Sp3 is expressed ubiquitously in the developing heart between E9.5 and E14.5. The expression pattern of Sp3 therefore does not provide an indication of the cell types directly affected by Sp3 deficiency during heart development.
![]() View larger version (125K): [in a new window] |
FIG. 3. Sp3 expression during cardiac development. Sections show Sp3 expression (a and c to k) and actin (b) in E9.5 to E14.5 WT hearts. At E10.5 not only the myocardium but also the endocardium and the endocardial cushion cells (Cu) of the outflow tract (OFT) are positive. This persists in the OFT at E12.5 and E14.5 (asterisks in panels d and e) as well as in the AVC (g and j). The mostly positive myocardium shows a mosaic pattern of positive and negative cells in some regions (arrows in panel k). Furthermore, there is a marked expression in the epicardium (EP) (j), the neural crest-derived condensed mesenchyme (CM) (h), and the smooth muscle cells of the aorta (Ao) (e and h). LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; V, ventricle. Bars, 100 µm (a to i) and 200 µm (j and k). The nuclear Sp3 staining is negative in Sp3–/– hearts (not shown).
|
Nkx2.5 is the first marker of mesodermal cells fated to cardiac development (5), regulating the expression of many structural cardiac muscle genes (47). Gata4 was studied because of its close interactions with Nkx2.5 (34). Tbx5 is involved in atrial and ventricular septation and is a regulator of several cardiac-specific genes (8, 17). We used atrial natriuretic factor (Anf) (26) and cardiac ankyrin repeat protein (Carp; Ankrd1) (58) as markers for late differentiation-related cardiac genes. Anf and Carp are expressed in the proliferating and developing myocardium. To differentiate between atrial and ventricular specification, we used the iroquois homeobox gene 4 (Irx4). This transcription factor regulates the chamber-specific myosin isoforms by activating the ventricular myosin heavy-chain 1 gene (Vmhc1) and inhibiting the atrial myosin heavy-chain 1 (Amhc1) in the ventricles (2). Finally, we used the myosin light-chain 2 (Mlc2a) (32) and the ventricular light-chain 2 (Mlc2v) genes (40) as markers for atrial specification. The contribution of neural crest cells in myocardialization and outflow tract formation was studied using the expression of Msx2, which is a marker for neural crest-derived mesenchymal cells (10). Finally, we examined the expression of the growth factors transforming growth factor ß1 (TGFß1) to -3, since TGFß2 is known to directly influence cardiac development (3, 45).
This analysis demonstrated that the expression of most of these genes did not appear to be different between WT and the Sp3–/– hearts at E10.5, E12.5, and E14.5. As an example, the expression pattern of the early cardiac gene Nkx2.5 at E12.5 and E14.5 is shown in Fig. 4a, b, e, and f. The only gene analyzed that showed a changed expression pattern was the Carp gene (Fig. 4c, d, g, and h). Here we found abnormal downregulation in Sp3–/– hearts after E12.5, specifically in the compact layer of the ventricular myocardium. At E14.5, Carp is still present in the right and left atria of Sp3–/– hearts, but expression of Carp is almost completely lost from the ventricular myocardium, with the exception of an area in the ventricular septum correlating with the position of the future ventricular conduction system. The aberrant downregulation of Carp expression after E12.5 occurs relatively late, when the Sp3–/– hearts already display severe abnormalities, and could be due to a secondary effect of the knockout phenotype. We therefore decided to investigate whether the Carp gene could be directly regulated by Sp3.
![]() View larger version (67K): [in a new window] |
FIG. 4. Expression of markers of cardiac development. In the myocardia of E12.5 and E14.5 Sp3–/– hearts (a, b, e, and f), Nkx2.5 remains expressed. Carp is downregulated after E12.5 in the absence of Sp3, as shown by in situ hybridization (c, d, g, and h). At E14.5, Carp expression is almost completely absent in the Sp3–/– heart. The remaining expression site at E14.5 correlates with the position of the future atrioventricular conduction system bridging the ventricular septum. Ao, aorta; LA, left atrium; RA, right atrium; RV, right ventricle. Bars, 100 µm.
|
![]() View larger version (57K): [in a new window] |
FIG. 5. Sp3 binds to the mouse Carp promoter in vitro and in vivo. (a) The Carp promoter region. The five Sp motifs (Sp C1 to Sp C5) are indicated, as are the Nkx2.5 and GATA motifs. (b) Gel retardation assay. The specificity of binding to the Sp C1 to Sp C5 oligonucleotides was analyzed through the addition of a 50-fold molar excess of a competitor oligonucleotide containing two Sp sites (18). Supershifts were performed to analyze the protein complexes with antibodies against Sp1 or Sp3. The arrows point to the different protein complexes formed; note that there are several isoforms of Sp3 (46). (c) ChIP reactions were performed on formaldehyde-cross-linked chromatin isolated from E14.5 ventricles, using the antibodies indicated. Enrichment for Carp promoter sequences was determined by real-time quantitative PCR, using amplification of an unrelated fragment of the Gata2 gene as a standard to normalize for the amount of template DNA in the reactions. (d) Real-time PCR analysis of Carp mRNA expression in E14.5 hearts of WT and Sp3 knockout (Sp3–/–) embryos. Expression of cyclophilin A mRNA was used to normalize for the amount of RNA. Error bars indicate standard errors of the means. The average Carp expression level in WT hearts was set to 100.
|
![]() View larger version (120K): [in a new window] |
FIG. 6. Expression of epicardial markers in Sp3–/– hearts. Sections of E12.5 (a to f) and E14.5 (g to l) hearts stained for Wt1 and E-cadherin. AVC region of an E12.5 WT heart (a) with detail of the left ventricle (LV) (b) showing the epicardial (EP) covering and the EPDCs in the subepicardial layer (arrows). The latter are missing in the mutant (e) taken from a similar position in a heart (d) displaying a common atrioventricular orifice, a thin spongy myocardium, and a deficient ventricular septum (VS). At E14.5 Wt1-stained EPDCs (arrows in panel g) are missing around the developing coronary vascular system (j). In the compact layer of the myocardium, fewer Wt1-stained EPDCs (arrow) are found in the mutant (k) than in the WT heart (h). In the Sp3–/– hearts E-cadherin (f and l) is upregulated compared to that in WT hearts (c and i), where EPDCs (arrows) are also located in the subepicardial region. Ao, aorta; LA, left atrium; RV, right ventricle. Bars, 60 µm (a, d, g, and j) and 30 µm (b, c, e, f, h, i, k, and l).
|
![]() View larger version (45K): [in a new window] |
FIG. 7. Gene expression profiling of E12.5 Sp3–/– hearts. RNA was isolated from E12.5 WT (n = 3) and Sp3–/– (n = 3) hearts, and gene expression profiles were determined using Affymetrix 430 2.0 Gene Chips. (a) Cluster analysis of the 116 probe sets representing 103 differentially expressed genes. Blue represents donwregulation and red upregulation in Sp3–/– hearts. (b) Biological processes represented by the 103 differentially expressed genes. ME, metabolism. Green, amino acid; yellow, carbohydrate; orange, lipid; purple, nucleotide; plum, redox; white, other. MB, membrane; ES, extracellular space; ST, signal transduction; NU, nuclear; MS, miscellaneous. Genes in gray boxes encode mitochondrial proteins. FC, change (n-fold). Blue and red are as defined for panel a.
|
|
|
|---|
The early defect in cardiac looping, resulting in an abnormal wide inner curvature at E10.5, points at a myocardial problem that might relate to defective myocardial-epicardial interactions (19). Remodeling of the primitive heart through looping is absolutely necessary to properly establish the definitive atrioventricular and ventriculoarterial connections. The observed inflow and outflow abnormalities can occur as direct consequences of defective cardiac looping. Furthermore, the observed common atrioventricular valve and atrioventricular septal defects also suggest that the development and fusion of the atrioventricular canal are abnormal. As we did not observe cases with persistent truncus arteriosus, outflow tract septation has been accomplished normally, indicating that neural crest cell migration to this area has been achieved (55). This is supported by the normal Msx2 expression pattern in the outflow tract (10). Evidence for abnormal myocardial differentiation is obtained from the ventricular myocardium, which failed to form a consistent compact layer in the Sp3–/– hearts. Furthermore, the ventricular wall was very thin, presenting myocardial perforations and fistulae after E12.5 in the majority of cases. This phenomenon might be due to an abnormal contribution of EPDCs to the heart (15, 19, 28, 35).
Wt1 is expressed in the epicardium and temporarily in EPDCs after EMT (38). Comparing WT and Sp3–/– hearts, we found that epicardial outgrowth had taken place normally but that EMT and subsequent differentiation of EPDCs might be abnormal. This is suggested from diminished Wt1 expression in the epicardium and the EPDCs in the compact myocardium of the ventricular wall. Wt1 is thought to stimulate the formation of EPDCs by activation of EMT (38). Wt1–/– embryos show epicardial defects with myocardial hypoplasia (30), which may be caused by disturbed formation of the subepicardial mesenchymal cells (i.e., EPDCs) by impaired EMT (54). To further substantiate disturbed EMT in Sp3–/– hearts we have used the cell-adhesion molecule E-cadherin. This marker should be downregulated during normal EMT (9). We found that E-cadherin expression was upregulated in the epicardium of the Sp3–/– hearts. This is consistent with diminished EMT and EPDC formation. Deregulated E-cadherin expression might explain the abnormal morphology and blebbing of the epicardial surface as well. We postulate that an abnormal cross talk between myocardium and EPDCs contributes to the myocardial pathology in Sp3–/– hearts. The role of Sp3 in regulation of Wt1 expression has not yet been described; however, there is evidence for a role of Sp1 (highly homologous to Sp3) in downregulation of Wt1 (11). Sp3 is expressed in both EPDCs and myocardium, and we observe changes in the expression of both Wt1 (EPDC specific) and Carp (myocardium specific). Further studies are necessary to unravel whether this is a concomitant "dual hit" or whether the primary defect resides in either the myocardial or EPDC compartment.
Sp3–/– versus other knockout models.
Several mouse knockout models present with cardiac and myocardial phenotypes that are comparable to those displayed by Sp3–/– embryos. For instance, TGFß2–/– embryos have malformations in the inflow and outflow tracts that are very similar to those observed in Sp3–/– embryos, but the severe thinning of the myocardium and the perforations are missing (3). Another example is provided by RxR
–/– embryos, which also show great variability in outflow and inflow malformations (22). Furthermore, RxR
–/– embryos display a serious epicardial insufficiency, leading to an abnormal cross talk of myocardium and epicardium and resulting in myocardial deficiency (28). Elevated levels of Mlc2a (14) and TGFß2 (31) have been observed in RxR
–/– embryos. We did not detect changes in the expression of these genes in the Sp3–/– hearts. Remarkably, the RxR
–/– embryos display a dramatic downregulation of Carp expression at E10.5 (43). The timing of this aberrant downregulation of Carp is different from that in Sp3–/– hearts, where it sets in after E12.5. Thus, although the phenotypes of several previously described knockouts display similarities to the cardiac phenotype of the Sp3 null mutants, none of those appear to recapitulate the Sp3 knockout phenotype completely.
Sp3 deficiency affects expression of the Carp gene. Carp transcription is mediated by the cooperative action of Gata4 and Nkx2.5 (33), which are not disturbed in their expression in the Sp3–/– heart. The specific loss of Carp expression in the ventricles can therefore not be directly attributed to these genes. The identification of four Sp binding sites in the 2.5-kb upstream regulating region of the Carp gene, a region essential for Carp expression (33), suggests that the Carp gene is a direct target of Sp3-mediated transcription. This is strongly supported by the ChIP assays demonstrating that Sp3 binds to this region of the Carp gene. Interestingly, we found that Nkx2.5 also interacts with this region in vivo. Thus, a model emerges in which Nkx2.5 and Gata4 initially activate the Carp gene. After this initial activation, Sp3 is required, most likely in conjunction with Nkx2.5 and Gata4, to maintain the appropriate expression pattern of Carp in the ventricles from E12.5 onwards. This is reminiscent of the role of the related family member Sp8 during early limb development, in which it is required to maintain, but not to initiate, Wnt/ß-catenin-dependent fibroblast growth factor-, sonic hedgehog, and bone morphogenetic protein-mediated signaling (4, 50).
Defining the molecular role of Sp3 in heart development.
The observed dysregulation of Carp expression occurs at a developmental time point when the Sp3–/– embryos already display major myocardial defects. The genome-wide gene expression profiling of E12.5 Sp3–/– hearts shows that, despite the severe myocardial phenotype, the expression of a relatively small number of genes is affected. In a bird's eye view, these data suggest that impaired small-molecule metabolism and abnormal cell-cell interactions may contribute to the Sp3–/– myocardial phenotype. However, this analysis does not point to a specific developmental pathway that is disturbed in Sp3–/– embryos. Several of the 103 differentially expressed genes are currently associated with cardiovascular phenotypes. P2rx4 encodes the ATP-gated P2X4 ion channel; it has a key role in the response of endothelial cells to changes in blood flow (56). Evc encodes a protein that is mutated in Ellis-van Creveld syndrome (44). About 60% of patients with Ellis-van Creveld syndrome have congenital cardiac defects, usually manifest as a common atrium. Itg4a encodes integrin
4; Itg4a knockout mice fail to form an epicardium and display cardiac hemorrhage (57). These genes provide leads for future studies of the Sp3–/– heart phenotype aimed at accurate positioning of Sp3 in the pathway of cardiac development. Since Sp3 is widely expressed, the Sp3–/– phenotype could be the result of improper functioning and interaction of several cell types that interact with myocardial development. A conditional knockout strategy should help to reveal which cell types contribute to the spectrum of the Sp3–/– heart phenotype.
We thank Jan Lens (LUMC Department of Anatomy and Embryology) for preparation of the figures and Wilfred van IJcken (Erasmus MC Department of Biomics) and Peter van der Spek (Erasmus MC Department of Bioinformatics) for microarray hybridizations and bioinformatics support, respectively.
Published ahead of print on 8 October 2007. ![]()
Present address: Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»